Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:03 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Alefacept in Kidney Transplant Recipients
NCT01433770 · University Hospitals Cleveland Medical Center · NA · withdrawn · last registry update 2012-02-22 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The drug will no longer be available in the United States.” | – | Registry record, University Hospitals Cleveland Medical Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2013-02-15Results posted on the registry: University of California, San Francisco, Intralesional Alefacept (NCT00678470)
- 2013-02-15Results posted on the registry: John Murray, alefacept (NCT00953329)
- 2012-08-03Results posted on the registry: Wake Forest University, Alefacept (NCT00655564)
- 2011-04-22Results posted on the registry: Astellas Pharma Inc, alefacept (NCT00658606)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision